Can a point-of-care urine protein assay monitor bladder cancer recurrence?

2006 ◽  
Vol 3 (9) ◽  
pp. 482-483
Author(s):  
Michael A O'Donnell
Keyword(s):  
Bladder Cancer ◽  
Point Of Care ◽  
Cancer Recurrence ◽  
Urine Protein ◽  
Protein Assay ◽  
Bladder Cancer Recurrence

238: Combined Effect of Apoptotic Biomarkers on Bladder Cancer Recurrence and Mortality after Radical Cystectomy

2007 ◽  
Vol 177 (4S) ◽  
pp. 79-80
Author(s):  
Jose A. Karam ◽  
Yair Lotan ◽  
Raheela Ashfaq ◽  
Claus G. Roehrborn ◽  
Arthur I. Sagalowsky ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Radical Cystectomy ◽  
Cancer Recurrence ◽  
Combined Effect ◽  
Bladder Cancer Recurrence

En bloc transurethral resection of bladder tumor: A review of the literature

2021 ◽  
pp. 205141582199373
Author(s):  
Jonathan Kopel ◽  
Pranav Sharma
Keyword(s):  
Bladder Cancer ◽  
Transurethral Resection ◽  
Bladder Tumor ◽  
Clinical Stage ◽  
Surgical Techniques ◽  
Cancer Recurrence ◽  
En Bloc ◽  
Level Of Evidence ◽  
Alternative Technologies ◽  
Bladder Cancer Recurrence

Bladder cancer remains one of the most common malignancies of the genitourinary tract. Transurethral resection of the bladder tumor (TURBT) via cystoscopy with examination under anesthesia remains the primary method for determining the diagnosis and clinical stage of bladder cancer. Given the substantial cost of treatment and risk of bladder cancer recurrence after TURBT, novel approaches to transurethral resection, such as the en bloc technique, have been developed in an attempt to address these limitations. In this review, we examined the postoperative and oncological outcomes of en bloc TURBT compared to traditional resection techniques. Further prospective clinical studies, however, are still necessary to determine whether these alternative technologies or surgical techniques may improve treatment in bladder cancer patients. Level of evidence: Not applicable.

scholarly journals Expression of tumor suppressive microRNA-34a is associated with a reduced risk of bladder cancer recurrence

2015 ◽  
Vol 137 (5) ◽  
pp. 1158-1166 ◽  
Author(s):  
Angeline S. Andrew ◽  
Carmen J. Marsit ◽  
Alan R. Schned ◽  
John D. Seigne ◽  
Karl T. Kelsey ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Cancer Recurrence ◽  
Bladder Cancer Recurrence ◽  
Reduced Risk

Serum Paraoxonase-1 Concentration as a Potential Predictor of Urinary Bladder Cancer Recurrence. A Five Year Follow-Up Study

2018 ◽  
Vol 49 (2) ◽  
pp. 119-122 ◽  
Author(s):  
Simona Iftimie ◽  
Anabel García-Heredia ◽  
Francesc Pujol-Bosch ◽  
Antoni Pont-Salvadó ◽  
Ana Felisa López-Azcona ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Urinary Bladder ◽  
Cancer Recurrence ◽  
Urinary Bladder Cancer ◽  
Paraoxonase 1 ◽  
Potential Predictor ◽  
Follow Up Study ◽  
Serum Paraoxonase ◽  
Bladder Cancer Recurrence

Multifocal Carcinoma In Situ of the Upper Tract Is Associated With High Risk of Bladder Cancer Recurrence

2012 ◽  
Vol 61 (5) ◽  
pp. 1069-1070 ◽  
Author(s):  
Evanguelos Xylinas ◽  
Michael Rink ◽  
Vitaly Margulis ◽  
Pierre Karakiewicz ◽  
Giacomo Novara ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
High Risk ◽  
Carcinoma In Situ ◽  
Cancer Recurrence ◽  
Upper Tract ◽  
Bladder Cancer Recurrence

Risk factors for bladder cancer recurrence survival in patients with upper-tract urothelial carcinoma

2018 ◽  
Vol 104 (6) ◽  
pp. 451-458 ◽  
Author(s):  
Yu-Peng Wu ◽  
Yun-Zhi Lin ◽  
Min-Yi Lin ◽  
Ting-Ting Lin ◽  
Shao-Hao Chen ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Urothelial Carcinoma ◽  
Cancer Recurrence ◽  
Cox Proportional Hazards Model ◽  
Upper Tract Urothelial Carcinoma ◽  
Intravesical Therapy ◽  
Low Grade ◽  
High Grade ◽  
Upper Tract ◽  
Bladder Cancer Recurrence

Purpose: The aim of this work was to investigate the predictive factors for bladder cancer recurrence survival (BCRS) in patients with upper-tract urothelial carcinoma (UTUC). Methods: We selected patients with UTUC who underwent segmental ureterectomy (Su) or nephroureterectomy (Nu) from 2004 to 2013 from the Surveillance, Epidemiology, and End Results (SEER) database. Patients with a history of intravesical therapy for bladder cancer and bladder cancer prior to the diagnosis of UTUC were excluded. We used Kaplan-Meier analysis, log-rank tests, and Cox proportional hazards model to compare overall survival, cancer-specific survival, and BCRS. Results: In a cohort of 1,454 patients, 169 (11.6%) had low-grade tumors and 1,285 (88.4%) had high-grade tumors; 239 (16.4%) underwent Su and 1,215 (83.6%) underwent Nu. We found that T4 grade (hazard ratio [HR] = 6.216; 95% confidence interval [CI], 3.197-12.087) and ureteral tumors (HR = 1.764; 95% CI, 1.173-2.652) were predictors of shorter BCRS, whereas Nu (HR = 0.608; 95% CI, 0.388-0.953) predicted longer BCRS. Five-year BCRS rates were low-grade tumors: 94.1%, high-grade tumors: 85.4% (p = 0.038); plus Su: 82.9%, and Nu: 87.6% (p = 0.016). Conclusions: Use of Su should be more selective for high-grade tumors, as it correlates with shorter BCRS. Tumors located in the ureter are associated with shorter BCRS than those located in the renal pelvis.

Sign in / Sign up

Export Citation Format

Share Document